Canakinumab, un anticuerpo monoclonal frente a IL-1β, con utilidad potencial en distintos procesos inflamatorios
Canakinumab, a monoclonal antibody against IL-1β, with potential utility in different inflammatory processes
Xavier Carné
Servicio de Farmacología Clínica, Unidad de Evaluación, Soporte y Prevención, IDIBAPS (Instituto de Investigaciones Biomédicas August Pi i Sunyer), Hospital Clínic, Barcelona, España
Leído
1179
Vecesse ha leído el artículo
212
Total PDF
967
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2017 10 | 2 | 2 | 4 |
| 2017 9 | 10 | 16 | 26 |
| 2017 8 | 8 | 2 | 10 |
| 2017 7 | 10 | 4 | 14 |
| 2017 6 | 7 | 8 | 15 |
| 2017 5 | 15 | 4 | 19 |
| 2017 4 | 18 | 2 | 20 |
| 2017 3 | 25 | 22 | 47 |
| 2017 2 | 14 | 3 | 17 |
| 2016 1 | 24 | 2 | 26 |
| 2016 12 | 42 | 7 | 49 |
| 2016 11 | 27 | 5 | 32 |
| 2016 10 | 36 | 4 | 40 |
| 2016 9 | 27 | 8 | 35 |
| 2016 8 | 32 | 9 | 41 |
| 2016 7 | 7 | 2 | 9 |
| 2016 6 | 12 | 5 | 17 |
| 2016 5 | 19 | 8 | 27 |
| 2016 4 | 4 | 2 | 6 |
| 2016 3 | 10 | 4 | 14 |
| 2016 2 | 12 | 8 | 20 |
| 2015 1 | 14 | 12 | 26 |
| 2015 12 | 9 | 6 | 15 |
| 2015 11 | 18 | 3 | 21 |
| 2015 10 | 17 | 9 | 26 |
| 2015 9 | 15 | 5 | 20 |
| 2015 8 | 6 | 5 | 11 |
| 2015 7 | 3 | 4 | 7 |
| 2015 6 | 3 | 3 | 6 |
| 2015 5 | 6 | 3 | 9 |
| 2015 4 | 4 | 7 | 11 |
| 2015 3 | 4 | 6 | 10 |
| 2015 2 | 8 | 2 | 10 |
| 2015 1 | 16 | 5 | 21 |
| 2014 12 | 7 | 4 | 11 |
| 2014 11 | 2 | 0 | 2 |
| 2014 10 | 6 | 0 | 6 |
| 2014 9 | 3 | 0 | 3 |
| 2014 8 | 4 | 3 | 7 |
| 2014 7 | 3 | 0 | 3 |
| 2014 6 | 4 | 1 | 5 |
| 2014 5 | 4 | 2 | 6 |
| 2014 4 | 4 | 1 | 5 |
| 2014 3 | 4 | 1 | 5 |
| 2014 2 | 5 | 1 | 6 |
| 2014 1 | 5 | 1 | 6 |
| 2013 10 | 0 | 1 | 1 |
| 2010 1 | 432 | 0 | 432 |
Mostrar todo
